# Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body

> **NCT06066112** · PHASE1 · UNKNOWN · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 100 (estimated)

## Conditions studied

- Bioequivalence
- Schizophrenia

## Interventions

- **DRUG:** Drug: Test (T) Amisulpride orally disintegrating tablets (200mg). Produced and supplied by Zezheng (Shanghai) Biotechnology Co., Ltd.

## Key facts

- **NCT ID:** NCT06066112
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-09-20
- **Primary completion:** 2023-10-07
- **Final completion:** 2024-03-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06066112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06066112, "Study on the Bioequivalence of Amisulpride Orally Disintegrating Tablets in Human Body". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06066112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*